Essentia’s software uses data analytics and behavioural finance research to help allocators and active asset managers make better decisions and improve their returns. Essentia expects to expand headcount and accelerate research and development following an investment by Northern Trust. Northern Trust … Continued
Archives for September 2021
Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), … Continued
Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation … Continued
Calculus is delighted to announce the appointments of Matthew Moynes and Frank Spurway as Investor Relations Assistant Director and Analyst respectively. Matthew joins Calculus from Barclays Wealth where he was the Head of Venture Capital Products responsible for managing the … Continued
Calculus EIS Fund was the first approved EIS Fund on the market 22nd iteration of the Fund launched this week The last 18 months have seen 10 exits across the EIS Funds including 6x return for ActiveOps Calculus Capital are … Continued
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid … Continued
Hardman & Co’s latest EIS Navigator Podcast Episode, hosted by Dr Brian Moretta FFA, featured Calculus Capital CEO John Glencross on the topic of “long term perspective on EIS and VCT investing”. You can listen below.